유전자 재조합 대상포진 백신 무엇이 다를까?
Herpes zoster (HZ) affects about one in three persons in their life time. Compared with the general population, older adults with immune senescence and individuals who are immunocompromised therapy are at increased risk for HZ, and its debilitating complications. To prevent HZ, two HZ vaccines, zost...
Saved in:
| Published in | The Korean journal of medicine Vol. 99; no. 4; pp. 180 - 188 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | Korean |
| Published |
대한내과학회
01.08.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1738-9364 2289-0769 |
| DOI | 10.3904/kjm.2024.99.4.180 |
Cover
| Summary: | Herpes zoster (HZ) affects about one in three persons in their life time. Compared with the general population, older adults with immune senescence and individuals who are immunocompromised therapy are at increased risk for HZ, and its debilitating complications. To prevent HZ, two HZ vaccines, zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV) are available. RZV is The Korean Society of Infectious Diseases revised guidelines for HZ vaccine in 2023, and recommended to vaccinate with RZV for adults ≥ aged 50 years and for severely immunocompromised adults aged ≥ 18 years. RZV is more effective for prevention of HZ than ZVL. RZV is nonreplicating and is thus safe in immunocompromised patients. RZV has clinically acceptable safety profile. This review will help clinicians update knowledge about RZV and identify eligible subjects who may benefit from HZ vaccinations. |
|---|---|
| Bibliography: | The Korean Association Of Internal Medicine KISTI1.1003/JNL.JAKO202426757814115 |
| ISSN: | 1738-9364 2289-0769 |
| DOI: | 10.3904/kjm.2024.99.4.180 |